Avalo Therapeutics Welcomes Jennifer Riley as Chief Strategy Officer
Avalo Therapeutics, Inc. (NASDAQ: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, has appointed Jennifer Riley as their new Chief Strategy Officer. This position is effective immediately. Ms. Riley's expertise is expected to elevate Avalo's corporate strategy, focusing on commercial and product pipeline advancements.
Jennifer Riley's Background
Dr. Garry Neil, the CEO and Chairman of Avalo, expressed excitement about Jennifer joining the team in this pivotal role. He noted her extensive leadership in immunology and strategic planning as key advantages for Avalo as they pursue their innovative treatments, particularly AVTX-009, which is currently in the LOTUS Phase 2 trial targeting hidradenitis suppurativa.
The Impact of AVTX-009
Ms. Riley highlighted the significant potential for AVTX-009 to emerge as a leading treatment for hidradenitis suppurativa (HS), a condition that presents high unmet medical need and is part of a fast-growing market predicted to exceed $10 billion. Her commitment to exploring the further applications of AVTX-009 demonstrates the ambition Avalo holds for its product pipeline, underlining IL-1?'s relevance in various inflammatory diseases.
Ms. Riley's Professional Journey
With over 20 years in the biotechnology and pharmaceutical sectors, Ms. Riley has been instrumental in shaping development strategies and optimizing portfolios for numerous firms. Prior to this, she led initiatives at Biogen, including overseeing the company's hemophilia portfolio. Her extensive background highlights her ability to deliver results in therapeutic areas spanning immunology and rare diseases.
Defined Role and Responsibilities
As Chief Strategy Officer, her responsibilities encompass refining Avalo's strategies for commercialization and innovation. This strategic role involves significant oversight of product development, aiming to ensure that Avalo not only meets but also anticipates market demands.
About Inducement Grants
Avalo's Board of Directors granted Ms. Riley a non-qualified stock option allowing her to purchase 150,000 shares of common stock. The structure of this option ensures that it vests over four years, reflecting Avalo's commitment to rewarding their leadership.
Unprecedented Market Opportunities
As Avalo Therapeutics continues to advance its lead asset, it is also pursuing two other drug candidates: quisovalimab (an anti-LIGHT mAb) and AVTX-008 (a BTLA agonist fusion protein). These additions reinforce Avalo's commitment to expanding its impact within the treatment of immune dysregulation.
LOTUS Trial Overview
The LOTUS Trial focuses on evaluating AVTX-009’s efficacy and safety through a structured, randomized approach across various dosing regimens. The trial aims to engage approximately 180 adults suffering from moderate to severe HS, establishing benchmarks based on key clinical responses.
Addressing Hidradenitis Suppurativa
Hidradenitis suppurativa is a distressing chronic inflammatory skin disorder characterized by painful nodules and abscesses, often located in areas such as the armpits and groin. This condition is frequently underdiagnosed, affecting up to 1.7% of the global population.
Contact Information for Inquiries
For media or investor-related inquiries, please reach out to Christopher Sullivan, CFO of Avalo Therapeutics, at ir@avalotx.com or call 410-803-6793. Additional inquiries can be directed to Lauren Glaser at Meru Advisors at lglaser@meruadvisors.com.
Frequently Asked Questions
Who is Jennifer Riley?
Jennifer Riley has been appointed as the Chief Strategy Officer at Avalo Therapeutics, bringing extensive leadership experience in biotechnology.
What is AVTX-009?
AVTX-009 is an anti-IL-1? monoclonal antibody currently in development for treating hidradenitis suppurativa and other inflammatory diseases.
What does the LOTUS Trial entail?
The LOTUS Trial assesses the efficacy and safety of AVTX-009 in adults with moderate to severe hidradenitis suppurativa.
How will Ms. Riley's role impact Avalo Therapeutics?
Ms. Riley's role will enhance Avalo's corporate strategy, focusing on innovation and commercialization of its drug candidates.
What is hidradenitis suppurativa?
Hidradenitis suppurativa is a chronic skin condition marked by painful abscesses that can significantly impact quality of life.
